Menu
Back to Journals » Clinical Ophthalmology » Volume 12
XEN glaucoma treatment system in the management of refractory glaucomas: a short review on trial data and potential role in clinical practice
Authors De Gregorio A, Pedrotti E, Stevan G, Bertoncello A, Morselli S
Received 11 January 2018
Accepted for publication 28 February 2018
Published 30 April 2018 Volume 2018:12 Pages 773—782
DOI https://doi.org/10.2147/OPTH.S146919
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 3
Editor who approved publication: Dr Scott Fraser
A De Gregorio,1 E Pedrotti,2 G Stevan,1 A Bertoncello,1 S Morselli1
1Ophthalmic Unit, San Bassiano Hospital, Bassano del Grappa, Italy; 2Eye Clinic, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
Abstract: The recent development of new devices that are significantly less invasive, collectively termed minimally invasive glaucoma surgery, offers new perspective of intraocular pressure reduction with less risk, short operating times, and rapid recovery. The aim of this work is to provide a panoramic review of the currently published clinical data to assess the potential role of XEN gel stent (Allergan PLC, Irvine, CA, USA) in the management of glaucoma, which is the only filtering minimally invasive glaucoma surgery device that allows the subconjunctival filtration. The ab interno placement of the XEN gel stent offers an alternative for lowering intraocular pressure in refractory glaucoma as a final step, and in patients intolerant to medical therapy as an early surgical approach with minimum conjunctival tissue disruption, restricted flow to avoid hypotony, and long-term safety.
Keywords: glaucoma, gel stent, minimally invasive, surgery, subconjunctival drainage
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.